Today's Top Gainer
| SYMBOL | CMP | Chg (%) |
|---|---|---|
Note:Top Gainer - Nifty 50 More
PR Newswire News On IndiaInfoline.com
-
SPARC is awaiting USFDA approval on its late stage innovative drugs, Elepsia (Epilepsy drug) and Xelpros (Glaucoma drug). Both ...
Accumulate Reco. Price: 383.95
-
Company operates an asset light model with lowest capital cost per operational bed than peers (Rs28lakh per bed in Q2FY18). We ...
Accumulate Reco. Price: 244.60